{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T21:05:17Z","timestamp":1776978317317,"version":"3.51.4"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Institut de Recherches Internationales Servier and Les Laboratoires Servier, Moscow, Russia"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>Pegaspargase, a well-established pediatric acute lymphoblastic leukemia (ALL) therapy, is available as a liquid formulation, and a lyophilized formulation with an improved shelf life. The pharmacokinetics and safety of lyophilized and liquid pegaspargase were assessed in pediatric patients with ALL in Russia. In Study 1, patients were randomly assigned (1:1) to receive 1 intravenous injection of lyophilized or liquid pegaspargase; patients who benefited from pegaspargase continued into Study 2 and received lyophilized pegaspargase every 2 weeks for 9 infusions. Of the 89 patients in Study 1, 74 continued into Study 2. In Study 1, maximum observed plasma asparaginase activity and area under the PAA-time curve were similar between groups. Geometric mean ratios were 93.5% (90% confidence interval [CI]: 82.9, 105.5) and 102.8% (90% CI: 91.4, 115.6), respectively; therefore, the 90% CIs were completely contained within the predefined acceptance interval of 80% to 125%. Pegaspargase-related adverse events occurred in 88.4% and 91.1% in the lyophilized and liquid groups, respectively, in Study 1. The safety profile of lyophilized pegaspargase after repeated infusion in Study 2 was consistent with the known safety profile of pegaspargase. Pharmacokinetic exposure does not depend on pegaspargase formulation. These studies support the use of lyophilized pegaspargase.<\/jats:p>","DOI":"10.1097\/mph.0000000000003176","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T14:06:38Z","timestamp":1775225198000},"page":"160-167","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Phase 2, Multicenter Studies of Pegaspargase in Pediatric Patients With Previously Untreated Acute Lymphoblastic Leukemia in Russia: Comparative Study of Liquid and Lyophilized Pegaspargase and Roll-Over Study of Lyophilized Formulation"],"prefix":"10.1097","volume":"48","author":[{"given":"Alexander I.","family":"Karachunskiy","sequence":"first","affiliation":[{"name":"Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology"},{"name":"Morozovskaya Children\u2019s City Clinical Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6498-9776","authenticated-orcid":false,"given":"Sergey G.","family":"Kovalenko","sequence":"additional","affiliation":[{"name":"Chelyabinsk Regional Children\u2019s Clinical Hospital, Chelyabinsk"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir V.","family":"Lebedev","sequence":"additional","affiliation":[{"name":"Regional Children\u2019s Clinical Hospital, Krasnodar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga I.","family":"Plaksina","sequence":"additional","affiliation":[{"name":"Nizhny Novgorod Regional Children\u2019s Clinical Hospital, Nizhny Novgorod"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia I.","family":"Ponomareva","sequence":"additional","affiliation":[{"name":"Pirogov Russian National Research Medical Institute, Moscow"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Seif","sequence":"additional","affiliation":[{"name":"Servier International Research Institute, Suresnes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Meng","sequence":"additional","affiliation":[{"name":"Servier BioInnovation, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey","family":"Grankov","sequence":"additional","affiliation":[{"name":"Servier International Research Institute, Suresnes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorene","family":"Simonot","sequence":"additional","affiliation":[{"name":"Servier International Research Institute, Suresnes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larisa G.","family":"Fechina","sequence":"additional","affiliation":[{"name":"Regional Children\u2019s Clinical Hospital"},{"name":"Institute of Medical Cells Technologies, Ekaterinburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulia V.","family":"Dinikina","sequence":"additional","affiliation":[{"name":"Federal State Budgetary Institution, V.A. Almazov National Medical Research Center of the Ministry of Health of the Russian Federation (V.A. Almazov NMRC), St Petersburg, Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"R1-20260423","first-page":"23","article-title":"Topics in pediatric leukemia\u2014acute lymphoblastic leukemia","volume":"7","author":"Esparza","year":"2005","journal-title":"MedGenMed"},{"issue":"suppl 5","key":"R4-20260423","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdw025","article-title":"Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Hoelzer","year":"2016","journal-title":"Ann Oncol"},{"key":"R5-20260423","doi-asserted-by":"crossref","first-page":"81","DOI":"10.6004\/jnccn.2020.0001","article-title":"Pediatric acute lymphoblastic leukemia, version 2.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Brown","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"R6-20260423","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/978-1-4615-4811-9_69","article-title":"The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia","volume":"457","author":"Asselin","year":"1999","journal-title":"Adv Exp Med Biol"},{"key":"R7-20260423","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","article-title":"A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children\u2019s Cancer Group study","volume":"99","author":"Avramis","year":"2002","journal-title":"Blood"},{"key":"R8-20260423","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S1470-2045(15)00363-0","article-title":"Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial","volume":"16","author":"Place","year":"2015","journal-title":"Lancet Oncol"},{"key":"R9-20260423","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1007\/s12325-019-00988-5","article-title":"Development of a lyophilized formulation of pegaspargase and comparability versus liquid pegaspargase","volume":"36","author":"Faschinger","year":"2019","journal-title":"Adv Ther"},{"key":"R10-20260423","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s12185-025-03976-4","article-title":"Phase 2 multicenter study of pegaspargase in Japanese patients with previously untreated acute lymphoblastic leukemia","volume":"122","author":"Koh","year":"2025","journal-title":"Int J Hematol"},{"key":"R11-20260423","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1634\/theoncologist.12-8-991","article-title":"FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL)","volume":"12","author":"Dinndorf","year":"2007","journal-title":"Oncologist"},{"key":"R12-20260423","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s40265-019-01120-1","article-title":"Pegaspargase: a review in acute lymphoblastic leukaemia","volume":"79","author":"Heo","year":"2019","journal-title":"Drugs"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003176","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T20:00:19Z","timestamp":1776974419000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000003176","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"2025-01-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}